Trial Profile
A Phase I Multicenter Study of Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 12 Feb 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Carboplatin; Cisplatin; Etoposide; Paclitaxel; Pemetrexed
- Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Non-small cell lung cancer; Oropharyngeal cancer; Small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Acronyms CLOVER
- Sponsors AstraZeneca
- 02 Feb 2024 Planned End Date changed from 29 Dec 2023 to 31 Dec 2024.
- 08 Oct 2021 Planned End Date changed from 31 Dec 2021 to 29 Dec 2023.
- 13 Nov 2020 Planned End Date changed from 4 Apr 2022 to 31 Dec 2021.